# US 10,500,240 B2 · Use of terminalia chebula extract for treatment of osteoarthritis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,500,240 B2
- Document ID: US10500240B2
- Status: Granted
- Kind: B2
- Application number: 14/578,793
- Filed: 2014-12-22
- Published: 2015-06-25
- Granted: 2019-12-10
- Earliest claimed: 2013-12-20
- Assignees: Natreon, Inc.
- Applicants: Natreon, Inc.
- Inventors: Sanyasi R. Kalidindi
- Web page: https://patentgrep.com/patent/US10500240B2

## CPC

- A61K 36/185: Magnoliopsida (dicotyledons)
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides an optimized and/or enriched hydrolyzable tannoid blend derived from Terminalia chebula. In an embodiment the present invention further relates to the use of an extract of Terminalia chebula for treatment of osteoarthritis. In another embodiment, a T. chebula extract composition contains about 8-25% by weight chebulagic acid, about 15-30% by weight chebulinic acid and about 10-40% by weight other low molecular weight hydrolyzable tannoids. This embodiment provides a T. chebula enriched tannoid blend composition (TC/enriched tannoid blend). In another embodiment, a method of treating osteoarthritis in an individual is provided, comprising administering to the individual in need thereof a therapeutically effective amount of the T. chebula extract composition. In yet another embodiment, a method of reducing pain and inflammation in an individual afflicted with osteoarthritis is provided, comprising orally administering to the individual in need thereof a therapeutically effective amount of the T. chebula extract composition.

## Claims

### Claim 1

A method of treating osteoarthritis in a mammal, comprising administering to a mammal in need thereof a therapeutically effective amount of a a composition comprising a Terminalia chebula extract comprising a hydrolyzable tannoid blend, said blend comprising about 8-25% by weight chebulagic acid based on the total weight of the extract and about 15-30% by weight chebulinic acid based on the total weight of the extract.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition is administered in a dosage from about 100 mg per day to about 5000 mg per day.

### Claim 3 (depends on 1)

The method of claim 1, wherein the composition is administered in a dosage from about 500 mg per day to about 1000 mg per day.

### Claim 4 (depends on 1)

The method of claim 1, wherein the mammal is selected from the group consisting of human, dog, cat, cow, horse, monkey, pig, sheep, cow, sheep, goat, and rabbit.

### Claim 5 (depends on 2)

The method of claim 2, wherein the mammal is a human.

### Claim 6 (depends on 3)

The method of claim 3, wherein the mammal is a human.

### Claim 7

A method of reducing pain and inflammation in an individual with osteoarthritis in need thereof, comprising orally administering to the individual in need thereof a therapeutically effective amount of a a composition comprising a Terminalia chebula extract comprising a hydrolyzable tannoid blend, said blend comprising about 8-25% by weight chebulagic acid based on the total weight of the extract and about 15-30% by weight chebulinic acid based on the total weight of the extract.

### Claim 8 (depends on 7)

The method of claim 7, wherein the composition is administered in a dosage from about 100 mg per day to about 5000 mg per day.

### Claim 9 (depends on 7)

The method of claim 7, wherein the composition is administered in a dosage from about 500 mg per day to about 1000 mg per day.

### Claim 10 (depends on 7)

The method of claim 7, wherein the individual is treated for about 2 weeks to about 12 weeks.

### Claim 11 (depends on 10)

The method of claim 10, wherein pain and inflammation in the individual is measured by a modified Western Ontario and McMaster Universities Osteoarthritis (mWOMAC) scale to provide an index score, wherein the mWOMAC index score is reduced by about 20% to about 40%.

### Claim 12 (depends on 10)

The method of claim 10, wherein pain and inflammation in the individual is measured by one of more subscales of Visual Analogue Scale (VAS), wherein the subscales are VAS-Pain, VAS-Stiffness, or VAS-Disability subscales and wherein the one or more subscales provide a score, and wherein the score is reduced by about 20% to about 40%.

### Claim 13 (depends on 10)

The method of claim 10, further comprising measuring knee swelling index, wherein the knee swelling index is reduced by about 5% to about 10%.